摘要
哌柏西利作为第一个上市的细胞周期蛋白依赖性激酶4和6抑制剂,显著改善了激素受体阳性、人表皮生长因子受体-2阴性乳腺癌的生存。哌柏西利的开发是抗肿瘤药物发展的一个重要里程碑。本文回顾了哌柏西利作用机制,总结了药物相关临床试验、相关不良反应以及药物应用等问题。
As the first cyclin-dependent kinases 4 and 6 inhibitors,palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer.Palbociclib is a crucial landmark in the development history of antineoplastic drugs.This article reviews the mechanism of palbociclib,and summarizes the clinical trials,side effects,and the application of palbociclib.
作者
郑方超
杜丰
刘昊琳
王雪
岳健
袁芃
ZHENG Fangchao;DU Feng;LIU Haolin;WANG Xue;YUE Jian;YUAN Peng(Department of VIP Medical,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),The VIPⅡGastrointestinal Cancer Division of Medical Department,Peking University Cancer Hospital and Institute,Beijing 100021,China;Xiangya School of Medicine,Changsha 410008,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第7期703-708,共6页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(82172650)
北京医学奖励基金(YXJL-2020-0941-0763)。
